vs
HANCOCK WHITNEY CORP（HWC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
HANCOCK WHITNEY CORP的季度营收约是Orthofix Medical Inc.的1.3倍（$295.0M vs $219.9M），HANCOCK WHITNEY CORP净利率更高（16.1% vs -1.0%，领先17.1%），Orthofix Medical Inc.同比增速更快（2.0% vs -19.7%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -9.4%）
汉考克惠特尼公司是总部位于美国密西西比州格尔夫波特的银行控股企业，在密西西比、阿拉巴马、佛罗里达、路易斯安那、得克萨斯五州共运营237家网点。它是新奥尔良圣徒队、路易斯安那州立大学体育队、路易斯安那大学拉法叶分校运动队的官方合作银行，独家发行对应队伍的官方借记卡，还独家提供LSU老虎队专属信用卡。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HWC vs OFIX — 直观对比
营收规模更大
HWC
是对方的1.3倍
$219.9M
营收增速更快
OFIX
高出21.7%
-19.7%
净利率更高
HWC
高出17.1%
-1.0%
两年增速更快
OFIX
近两年复合增速
-9.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $295.0M | $219.9M |
| 净利润 | $47.4M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 16.1% | -1.0% |
| 营收同比 | -19.7% | 2.0% |
| 净利润同比 | -60.3% | 92.4% |
| 每股收益（稀释后） | $0.57 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HWCOFIX
| Q1 26 | $295.0M | — | ||
| Q4 25 | $389.3M | $219.9M | ||
| Q3 25 | $385.7M | $205.6M | ||
| Q2 25 | $375.5M | $203.1M | ||
| Q1 25 | $364.7M | $193.6M | ||
| Q4 24 | $364.8M | $215.7M | ||
| Q3 24 | $367.7M | $196.6M | ||
| Q2 24 | $359.6M | $198.6M |
净利润HWCOFIX
| Q1 26 | $47.4M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $127.5M | $-22.8M | ||
| Q2 25 | — | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $115.6M | $-27.4M | ||
| Q2 24 | — | $-33.4M |
毛利率HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 40.7% | 0.2% | ||
| Q3 25 | 41.6% | -8.3% | ||
| Q2 25 | 38.5% | -7.9% | ||
| Q1 25 | 40.9% | -25.2% | ||
| Q4 24 | 41.3% | -5.3% | ||
| Q3 24 | 39.5% | -9.6% | ||
| Q2 24 | 40.3% | -12.5% |
净利率HWCOFIX
| Q1 26 | 16.1% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 33.0% | -11.1% | ||
| Q2 25 | — | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 31.4% | -13.9% | ||
| Q2 24 | — | -16.8% |
每股收益（稀释后）HWCOFIX
| Q1 26 | $0.57 | — | ||
| Q4 25 | $1.48 | $-0.05 | ||
| Q3 25 | $1.49 | $-0.57 | ||
| Q2 25 | $1.32 | $-0.36 | ||
| Q1 25 | $1.38 | $-1.35 | ||
| Q4 24 | $1.40 | $-0.76 | ||
| Q3 24 | $1.33 | $-0.71 | ||
| Q2 24 | $1.31 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $223.7M | $82.0M |
| 总债务越低越好 | $1.6B | — |
| 股东权益账面价值 | — | $450.0M |
| 总资产 | $35.5B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HWCOFIX
| Q1 26 | $223.7M | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务HWCOFIX
| Q1 26 | $1.6B | — | ||
| Q4 25 | $199.4M | — | ||
| Q3 25 | $210.7M | $157.2M | ||
| Q2 25 | $210.6M | $157.0M | ||
| Q1 25 | $210.6M | $156.9M | ||
| Q4 24 | $210.5M | $157.0M | ||
| Q3 24 | $236.4M | $118.5M | ||
| Q2 24 | $236.4M | $118.0M |
股东权益HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $4.5B | $450.0M | ||
| Q3 25 | $4.5B | $442.5M | ||
| Q2 25 | $4.4B | $458.3M | ||
| Q1 25 | $4.3B | $458.3M | ||
| Q4 24 | $4.1B | $503.1M | ||
| Q3 24 | $4.2B | $525.9M | ||
| Q2 24 | $3.9B | $546.0M |
总资产HWCOFIX
| Q1 26 | $35.5B | — | ||
| Q4 25 | $35.5B | $850.6M | ||
| Q3 25 | $35.8B | $832.6M | ||
| Q2 25 | $35.2B | $837.2M | ||
| Q1 25 | $34.8B | $823.1M | ||
| Q4 24 | $35.1B | $893.3M | ||
| Q3 24 | $35.2B | $867.9M | ||
| Q2 24 | $35.4B | $882.0M |
负债/权益比HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.05× | 0.36× | ||
| Q2 25 | 0.05× | 0.34× | ||
| Q1 25 | 0.05× | 0.34× | ||
| Q4 24 | 0.05× | 0.31× | ||
| Q3 24 | 0.06× | 0.23× | ||
| Q2 24 | 0.06× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $541.8M | $27.7M | ||
| Q3 25 | $158.8M | $12.4M | ||
| Q2 25 | $125.8M | $11.6M | ||
| Q1 25 | $104.2M | $-18.4M | ||
| Q4 24 | $625.7M | $23.7M | ||
| Q3 24 | $162.5M | $11.7M | ||
| Q2 24 | $105.0M | $9.0M |
自由现金流HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | $523.1M | $16.8M | ||
| Q3 25 | $155.0M | $2.5M | ||
| Q2 25 | $122.0M | $4.5M | ||
| Q1 25 | $100.2M | $-25.1M | ||
| Q4 24 | $615.5M | $15.2M | ||
| Q3 24 | $158.6M | $6.3M | ||
| Q2 24 | $103.7M | $-360.0K |
自由现金流率HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 134.4% | 7.6% | ||
| Q3 25 | 40.2% | 1.2% | ||
| Q2 25 | 32.5% | 2.2% | ||
| Q1 25 | 27.5% | -13.0% | ||
| Q4 24 | 168.7% | 7.0% | ||
| Q3 24 | 43.1% | 3.2% | ||
| Q2 24 | 28.8% | -0.2% |
资本支出强度HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | 4.8% | 4.9% | ||
| Q3 25 | 1.0% | 4.8% | ||
| Q2 25 | 1.0% | 3.5% | ||
| Q1 25 | 1.1% | 3.5% | ||
| Q4 24 | 2.8% | 4.0% | ||
| Q3 24 | 1.1% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% |
现金转化率HWCOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HWC
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
